A new Chinese vaccine made from chimpanzee blood has entered the third phase of clinical trials



[ad_1]

Portfolio Signature for Christmas too.

Key analysis and exclusive content under the tree. You can even give someone a last minute gift with a one-year subscription to Portfolio Signature. And if you buy an annual subscription for multiple friends, friends and family at the same time, you can also get a quantity discount. So in addition to being a useful gift for the holidays, it can even support the production of quality inexpensive content. Know more

It is based in Kunming, South China A vaccine developed by a pharmaceutical company called Walvax Biotechnology in collaboration with researchers at Tsinghua University in Beijing and Tianjin Medical University is based on an adenovirus vector, and produced using chimpanzee blood.

Its mechanism of action is based precisely on the fact that the antibodies capable of neutralizing the adenoviruses carried by chimpanzees are not normally found in the human body. As a result, the vaccine is unlikely to cause an adverse reaction in the human body, but can provide strong immunity after vaccination Xinhua quoted the head of the investigation team, who also said that no serious side effects were observed in the animal experiments.

The third phase of clinical trials of the vaccine will be carried out abroad in the countries hardest hit by the epidemic, as there are currently not enough Covid-19 patients in China for this.

Construction of the vaccine production facility began on Sunday in one of Beijing’s southern districts, so that as soon as the results of clinical trials confirm the effectiveness of the vaccine, the facility is ready for mass production. Walwax said the vaccine could receive the necessary permits to enter the market in mid-2021, and the annual production capacity will exceed 200 million doses.

In addition to the Walwax-fle vaccine, five coronavirus vaccines developed in China are currently in the third phase of clinical trials. Among them, the joint vaccine of the Chinese Academy of Military Sciences and Chinese pharmaceutical manufacturer CanSino Biologics is also based on the adenovirus vector.

Cover image source: Getty Images.



[ad_2]